Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
4 hedge funds and large institutions have $2.75M invested in Hepion Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
33% less funds holding
Funds holding: 6 → 4 (-2)
39% less capital invested
Capital invested by funds: $4.51M → $2.75M (-$1.76M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$1.39M |
| 2 |
Morgan Stanley
New York
|
-$307K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
-$1K |
| 4 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$1K |
HEPA Hedge Fund Activity: Q3 2017 in Review
4 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2017, worth a combined $2.75M — down 39% from $4.51M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of HEPA and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Anson Funds Management, exiting entirely with an estimated $1.39M sold.
- 4 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q3 2017, down from 6 in Q2 2017.
- Funds reported $2.75M of Hepion Pharmaceuticals stock for Q3 2017, down 39% quarter-over-quarter.
- 0 funds opened new Hepion Pharmaceuticals positions in Q3 2017 and 2 closed out, a net change of -2 holders.
- The largest Hepion Pharmaceuticals seller in Q3 2017 was Anson Funds Management, an estimated $1.39M sold.
Based on aggregated 13F filings for Q3 2017.